medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2017, Número 12

<< Anterior Siguiente >>

Ginecol Obstet Mex 2017; 85 (12)


Prevalencia y tipificación de genotipos de virus del papiloma humano en mujeres del área metropolitana del Valle de México

Heredia-Caballero ÁG, Palacios-López GG, Castillo-Hernández MC, Hernández-Bueno AI, Medina-Arizmendi FV

Idioma: Español
Referencias bibliográficas: 37
Paginas: 809-818
Archivo PDF: 427.58 Kb.


RESUMEN

Objetivo: determinar la prevalencia del virus del papiloma humano y describir los genotipos más frecuentes.
Materiales y Métodos: estudio descriptivo y ambispectivo efectuado en pacientes atendidas en la consulta externa del Hospital Militar de Especialidades de la Mujer y Neonatología, entre marzo y octubre de 2015, para prueba de PCR con fines de detección del virus del papiloma humano (Digene® HC2 DNA Collection Device).
Resultados: se registraron 142 pacientes mujeres. La prevalencia del VPH fue de 9%. El 77% estaba en riesgo alto, de las que el serotipo 56 fue el más frecuente. El resto (33%) se clasificó con riesgo bajo (n = 3) de diferente tipo, pero ninguno 6 u 8. En cuanto a la diferencia de medias con t de Student para el número de parejas sexuales y edad, respecto del resultado de la prueba de PCR, no se obtuvieron resultados estadísticamente significativos.
Conclusiones: la prevalencia del virus del papiloma humano varía entre los diferentes estudios realizados en México. En el sistema de salud se requiere un programa organizado para poder disminuir la prevalencia del VPH.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bernard E, Pons-Salort M, Favre M Heard I, et al. Comparing human papillomavirus prevalences in women with normal cytology or invasive cervical cancer to rank genotypes according to their oncogenic potential: a meta-analysis of observational studie. BMC Infect Dis 2013;13:373.

  2. Ciapponi A, Bardach A, Glujowsky D, Gibbons L Picconi MA. type-specific hpv prevalence in cervical cancer and highgrade lesions in Latin America and the Caribbean: systematic review and meta-analysis. PLoS ONE 2011;6(10):35-40.

  3. Muñoz N, Bosch FX, Castellsagué X, Díaz M, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;20(10):278-85.

  4. Vilela-Desposorio C, Rodríguez-Delfín LA, Castro-Poémape A. Detección del virus del papiloma humano mediante reacción en cadena de la polimerasa y su relación con los resultados del Pap convencional. Mosaico Cient 2006;3(2):30-35.

  5. Lewis M. Análisis de la situación del Cáncer Cervicouterino en América Latina y el Caribe. OPS. 2004;3:15-30.

  6. Velázquez-Márquez N, Jiménez-Aranda L, Sánchez-Alonso P. Human papiloma virus infection in women from Tlaxcala, Mexico. Braz J Microbiol 2010;41:749-756.

  7. Martín P, Kilany L, García D, López-García AM, Martín- Azaña, et al. Human papillomavirus genotype distribution in Madrid and correlation with cytological data. BMC infect Dis 2011;(1):316.

  8. de Sanjosé S, Diaz M, Castellsagué X, Clifford G, et al. Worldwide prevalence and genotype distribution of cervical. Lancet Infect Dis 2007;(7):453-459.

  9. Lazcano-Ponce EC, Nájera-Aguilar P, Buiatti E, Alonso-de- Ruíz P, et al. The cervical cancer screening program in Mexico: problems with access and coverage. Cancer Causes Control 1997;8:698-704.

  10. Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004. National Cancer Institute; 2007. [en línea]. Dirección URL: < https://seer.cancer.gov/archive/ csr/1975_2004/>.

  11. Deluca GD, Lucer RH, Martin de Civetta MT, Vicente L, et al. A human papillomavirus genotypes in women with cervical cytological. Rev Inst Med Trop São Paulo 2004;46:1-9.

  12. de Sanjose S, Quint WG, Alemany L, Geraets DT, et al. Human papillomavirus DNA in women with normal cytology. Lancet Oncol 2010;11:1048-56.

  13. Lazcano-Ponce E, Herrero R, Munoz N, Cruz A, et al. Epidemiology of HPV infection among mexican women with normal cervical cytology. Int J Cancer 2001;91(3):412-420.

  14. Possatti-Resende J, Fregnani JH, Kerr LM, Mauad EC, et al. The Accuracy of p16/Ki-67 and HPV Test in the Detection of CIN2/3 in Women Diagnosed with ASC-US or LSIL. PLos One 2015;3:1-10.

  15. Programa de acción específica del cáncer cervicouterino. [en línea]. Direcciónn URL: < http://www.cnegsr.salud. gob.mx/contenidos/Programas_de_Accion/cancermama/ ProgAccionCancer.html>.

  16. Sherman ME, Wang SS, Wheeler CM, Rich L, et al. Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions. Cancer Epidemiol Biomarkers Prev 2003;12(10):1038-44.

  17. Snijders PJ, Hogewoning CJ, Hesselink AT, Berkhof J, et al. Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology. Int J Cancer 2006;119:1102-7.

  18. Sherlaw-Johnson C, Gallivan S, Jenkins D. Withdrawing low risk women from cervical screening programmes: mathematical modelling study. BMJ 1999;318:356-60.

  19. Burk RD, Kelly P, Feldham J, Bromberg J, Vermund SH, et al. Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. Sex Transm Dis 1996;23:333-41.

  20. Grainge MJ, Seth R, Guo, Neal KR, et al. Cervical human papillomavirus screening among older women; emerging infectious diseases. Emerg Infect Dis 2005;11(11):1680-5.

  21. Arbyn M, Sasieni P, Meijer C, Clavel C, et al. Chapter 9: Clinical applications of HPV testing: A summary of metaanalyses. Vaccine 2006;24:S3/78-S3/89.

  22. Petry KU, Menton S, Menton M, van Loenen-Frosch F, et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 2003;88:1570-1577.

  23. Peto J, Gilham C, Fletcher O, MAtthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004;364:249-56

  24. Kitchener HC, Wheeler P, Desai M, et al. The ARTISTIC Trial: A Randomised Trial In Screening To Improve Cytology. 21st International Papillomavirus Conference 2004, Feb 20–26, 2004; Mexico City, Mexico (abstr 268).

  25. Lopez-Rivera M, Medel-Flores MO, Villalba-Magdaleno JD, Sanchez-Monroy V. Prevalence of human papillomavirus in women from Mexico City. Infect Dis Obstet Gynecol 2012;(2012):1-4.

  26. Orozco-Colin A, Carrillo-Garcia A, Mendez-Tenorio A, Ponce-de-León S, et al. Geographical variation in human papillomavirus prevalence in Mexican women with normal cytology. Int J Infect Dis 2010;14(12):e1082-e1087.

  27. Velazquez- Marquez Noe, Jimenez-Aranda Lucio, Sanchez- Alonso Patricia, “Human papiloma virus infection in women from Tlaxcala, Mexico”, Brazilian Journal of Microbiology vol. 41 2010: 749-756.

  28. Velazquez-Marquez N, Jiménez-Aranda L, Sánchez-Alonso P. Human papiloma virus infection in women from Tlaxcala, Mexico. Braz J Microbiol 2010;41:749-756.

  29. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high risk area for cervical cancer. J Infect Dis. 1999;180:1415-23.

  30. Munoz N, Mendez F, Posso H, Molano M, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis. 2004;190:2077-87.

  31. Castle PE, Schiffman M, Herrero R, Hildesheim A, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005;191:1808-16.

  32. Clifford G, Muños H, Snijders P, Muñoz N, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005;366:991-998.

  33. Urse RG, Onofriescu M, Nemescu D, Iancu LS. HPV prevalence and type distribution in women with or without cervical lesions in the Northeast region of Romania. Virol J 2011;8:558.

  34. Hakim AA, Dinh TA. Worldwide Impact of the Human papillomavirus vaccine. Curr Treat Opt Oncol 2009;10:44-53.

  35. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12.

  36. Mammas IN, Vageli D, Spandidos D. Geographic variations of human papilloma virus infection and their possible impact on the effectiveness of the vaccination programme. Oncol Rep 2008;20:141-145.

  37. Serrano B, Alemany L, Tous S, Bruni L, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 2012;7(1):38.




2020     |     www.medigraphic.com